We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Futura Medical

FY21 results reassure on cash runway and hint at EU deal

Lighthouse | 26 April 2022

Arecor Therapeutics

Ambitious, focussed, and delivering on its promise

Update | 25 April 2022

Scancell

A fresh impetus in delivering immune-oncology vaccines

Outlook | 12 April 2022

MaxCyte

Sustained FY21 growth with significantly more potential

Update | 06 April 2022

Avacta

FY21 results: a year of frustrations and opportunities

Update | 06 April 2022

Redx Pharma

RXC008 nominated as GI-ROCK drug candidate

Lighthouse | 30 March 2022

Futura Medical

Menarini to commercialise MED3000 in South Korea

Lighthouse | 23 March 2022

MaxCyte

Opening the next chapter

Outlook | 09 March 2022

HUTCHMED

A genuinely global R&D-driven biopharma business

Lighthouse | 03 March 2022

Allergy Therapeutics

Solid commercial performance with major R&D upside

Outlook | 03 March 2022
1 2 3 4 5 6 7 8 9 10 >
311 results found.